Table 4.

Known interactions among the CPIs predicted by the multiple QSAR models for approved drugs.

Drug Name	Predicted Target	Known Activity	Reference
Enfuvirtide	GP41	IC50 = 90.2 nM	[35]
Delavirdine	RT	IC50 = 0.17 μM	[36]
Didanosine	RT	IC50 = 4.6 μM	[42]
Lamivudine	RT	IC50 = 0.60 μM	[42]
Stavudine	RT	IC50 = 1.9 μM	[42]
Zalcitabine	RT	IC50 = 0.13 μM	[42]
Zidovudine	RT	IC50 = 0.13 μM	[42]
Dolutegravir	RT	Inactive	[50]
Dolutegravir	IN	IC50 = 2.7 nM	[43]
Elvitegravir	RT	IC50 = 91 μM	[44]
Elvitegravir	IN	IC50 = 28 nM	[44]
Amprenavir	PR	IC50 = 0.15 μM	[45]
Atazanavir	RT	IC50 = 26 nM	[46]
Atazanavir	PR	IC50 = 3.5 nM	[47]
Darunavir	PR	IC50 = 3.0 nM	[47]
Indinavir	RT	Inconclusive	[51]
Indinavir	PR	IC50 < 0.01 μM	[51]
Nelfinavir	PR	IC50 = 0.53 nM	[48]
Ritonavir	PR	IC50 = 0.6 nM	[49]
Ritonavir	CYP3A	IC50 = 0.11 μM	[49]
Tipranavir	PR	IC50 = 0.03 μM	[37]
Cobicistat	PR	IC50 = 0.15 μM	[49]
Cobicistat	CYP3A	IC50 > 30 μM	[49]
Telaprevir	NS3/4A	IC50 = 0.2 μM	[38]
Simeprevir	NS3/4A	IC50 = 10 nM	[39]
Grazoprevir	NS3/4A	IC50 = 0.07 nM	[40]
Dasabuvir	NS5B	IC50 = 0.6 μM	[41]